>
Fa   |   Ar   |   En
   Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: A randomized placebo-controlled trial  
   
نویسنده duval x. ,van der werf s. ,blanchon t. ,mosnier a. ,bouscambert-duchamp m. ,tibi a. ,enouf v. ,charlois-ou c. ,vincent c. ,andreoletti l. ,tubach f. ,lina b. ,mentré f. ,leport c.
منبع plos medicine - 2010 - دوره : 7 - شماره : 11
چکیده    Background:neuraminidase inhibitors are thought to be efficacious in reducing the time to alleviation of symptoms in outpatients with seasonal influenza. the objective of this study was to compare the short-term virological efficacy of oseltamivir-zanamivir combination versus each monotherapy plus placebo. methods and findings:we conducted a randomized placebo-controlled trial with 145 general practitioners throughout france during the 2008-2009 seasonal influenza epidemic. patients,general practitioners,and outcome assessors were all blinded to treatment assignment. adult outpatients presenting influenza-like illness for less than 36 hours and a positive influenza a rapid test diagnosis were randomized to oseltamivir 75 mg orally twice daily plus zanamivir 10 mg by inhalation twice daily (oz),oseltamivir plus inhaled placebo (o),or zanamivir plus oral placebo (z). treatment efficacy was assessed virologically according to the proportion of patients with nasal influenza reverse transcription (rt)-pcr below 200 copies genome equivalent (cgeq)/ml at day 2 (primary outcome),and clinically to the time to alleviation of symptoms until day 14. overall 541 patients (of the 900 planned) were included (oz,n = 192; o,n = 176; z,n = 173),49% male,mean age 39 years. in the intention-to-treat analysis conducted in the 447 patients with rt-pcr-confirmed influenza a,46%,59%,and 34% in oz (n = 157),o (n = 141),and z (n = 149) arms had rt-pcr<200 cgeq/ml (213.0%,95% confidence interval [ci] 223.1 to 22.9,p = 0.025; +12.3%,95% ci 2.39?22.2,p = 0.028 for oz/o and oz/z comparisons). mean day 0 to day 2 viral load decrease was 2.14,2.49,and 1.68 log10 cgeq/μl (p = 0.060,p = 0.016 for oz/o and oz/z). median time to alleviation of symptoms was 4.0,3.0,and 4.0 days (+1.0,95% ci 0.0?4.0,p = 0.018; +0.0,95% ci 23.0 to 3.0,p = 0.960 for oz/o and oz/z). four severe adverse events were observed. nausea and/or vomiting tended to be more frequent in the combination arm (oz,n = 13; o,n=4; and z,n = 5 patients,respectively). conclusions: in adults with seasonal influenza a mainly h3n2 virus infection,the oseltamivir-zanamivir combination appeared less effective than oseltamivir monotherapy,and not significantly more effective than zanamivir monotherapy. despite the theoretical potential for the reduction of the emergence of antiviral resistance,the lower effectiveness of this combination calls for caution in its use in clinical practice. © 2010 duval et al.
آدرس inserm cic 007,aphp,hôpital bichat,paris,france,inserm u738,paris,france,université paris diderot,paris 7,ufr de médecine,site bichat,paris, France, institut pasteur,centre national de référence des virus influenzae (région-nord),unité de génétique moléculaire des virus a arn,paris,france,cnrs ura3015,paris,france,université paris diderot,paris 7,ufr sciences du vivant,paris, France, inserm upmc umr-s 707,faculté de médecine pierre et marie curie,paris,france,université pierre et marie curie,paris 6,ufr de médecine,paris, France, réseau des groupes régionaux d'observation de la grippe (grog),coordination nationale,paris, France, hospices civils de lyon,centre national de référence des virus influenzae (région-sud),ghe,bron,france,université lyon 1,vir pat h,lyon, France, aphp- agence géné rale des equipements et produits de santé,unité essais cliniques,paris,france,université paris descartes,paris 5,faculté de pharmacie,paris, France, institut pasteur,centre national de référence des virus influenzae (région-nord),unité de génétique moléculaire des virus a arn,paris, France, université paris diderot,paris 7,ufr de médecine,site bichat,laboratoire de recherche en pathologie infectieuse,paris, France, inserm u738,paris,france,université paris diderot,paris 7,ufr de médecine,site bichat,paris,france,aphp,hôpital bichat,unité de biostatistiques,paris, France, hôpital robert debré,unité de virologie mé dicale,reims,france,unité de virologie médicale et moléculaire,faculté de médecine université champagne-ardenne,reims, France, inserm u738,paris,france,université paris diderot,paris 7,ufr de médecine,site bichat,paris,france,aphp hôpital bichat,département d'epidémiologie,biostatistiques et recherche clinique,paris, France, hospices civils de lyon,centre national de référence des virus influenzae (région-sud),ghe,bron,france,université lyon 1,vir pat h,lyon, France, inserm u738,paris,france,université paris diderot,paris 7,ufr de médecine,site bichat,paris,france,aphp,hôpital bichat,unité de biostatistiques,paris, France, université paris diderot,paris 7,ufr de médecine,site bichat,laboratoire de recherche en pathologie infectieuse,paris,france,aphp,unité de coordination des risques epidémiques et biologiques,paris, France
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved